<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Adalimumab</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Adalimumab">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Adalimumab</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Adalimumab</b>, sold under the brand name <b>Humira</b> among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.<span class="mw-ref" id="cite_ref-AHFS2019_5-0"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-BNF76_6-0"><a href="#cite_note-BNF76-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-hidradenitis_suppurativa_7-0"><a href="#cite_note-hidradenitis_suppurativa-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span> Use is generally only recommended in people who have not responded to other treatments.<span class="mw-ref" id="cite_ref-BNF76_6-1"><a href="#cite_note-BNF76-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It is used by injection under the skin.<span class="mw-ref" id="cite_ref-AHFS2019_5-1"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>



<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Adalimumab</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Adalimumab_structure.png" tppabs="https://ptable.com/wiki/compounds/I/m/Adalimumab_structure.png" data-file-width="446" data-file-height="478" data-file-type="bitmap" height="236" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Monoclonal antibody</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Type</th><td>Whole antibody</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Source</th><td>Human</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Target</th><td>TNF alpha</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Humira, Mabura, Exemptia, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>adalimumab-adaz, adalimumab-adbm, adalimumab-afzb, adalimumab-atto, adalimumab-bwwd, adalimumab-fkjp</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/adalimumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/adalimumab.html'" tppabs="https://www.drugs.com/monograph/adalimumab.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a603010.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a603010.html'" tppabs="https://medlineplus.gov/druginfo/meds/a603010.html" class="external text external">a603010</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Adalimumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Adalimumab'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Adalimumab" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Adalimumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Adalimumab'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Adalimumab" class="external text external">Adalimumab</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>C<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>TNF inhibitor</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AB04<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AB04  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AB04'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AB04" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span><span class="mw-ref" id="cite_ref-Humira_SmPC_2-0"><a href="#cite_note-Humira_SmPC-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span><span class="mw-ref" id="cite_ref-Humira_FDA_label_3-0"><a href="#cite_note-Humira_FDA_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></li>
<li><small><abbr class="country-name">EU</abbr>:</small><span> </span>Rx-only<span> </span><span class="mw-ref" id="cite_ref-Humira_EPAR_4-0"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>64% (subcutaneous), 0% (By mouth)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>10–20 days</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=331731-18-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=331731-18-1'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=331731-18-1" class="external text external">331731-18-1</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00051  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00051'" tppabs="https://www.drugbank.ca/drugs/DB00051" class="external text external">DB00051</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=FYS6T7F842  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=FYS6T7F842'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=FYS6T7F842" class="external text external">FYS6T7F842</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D02597  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D02597'" tppabs="https://www.kegg.jp/entry/D02597" class="external text external">D02597</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201580  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201580'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201580" class="external text external">ChEMBL1201580</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.224.376  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.224.376'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.224.376" class="external text external">100.224.376</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>6428</sub><span>H</span><sub>9912</sub><span>N</span><sub>1694</sub><span>O</span><sub>1987</sub><span>S</span><sub>46</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td>144190.3<span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28C%29%28C%29C%28%3DO%29OC1%3DCC%3DC%28C%3DC1%29S%28%3DO%29%28%3DO%29NC1%3DCC%3DCC%3DC1C%28%3DO%29NCC%28O%29%3DO  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28C%29%28C%29C%28%3DO%29OC1%3DCC%3DC%28C%3DC1%29S%28%3DO%29%28%3DO%29NC1%3DCC%3DCC%3DC1C%28%3DO%29NCC%28O%29%3DO'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC%28C%29%28C%29C%28%3DO%29OC1%3DCC%3DC%28C%3DC1%29S%28%3DO%29%28%3DO%29NC1%3DCC%3DCC%3DC1C%28%3DO%29NCC%28O%29%3DO" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC(C)(C)C(=O)OC1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477241856&page2=Adalimumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477241856&page2=Adalimumab'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=477241856&page2=Adalimumab" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


<p>Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache.<span class="mw-ref" id="cite_ref-AHFS2019_5-2"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, multiple sclerosis, heart failure, liver failure, and aplastic anemia.<span class="mw-ref" id="cite_ref-AHFS2019_5-3"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Use during pregnancy is not recommended, while some feel use during breastfeeding may be safe.<span class="mw-ref" id="cite_ref-BNF76_6-2"><a href="#cite_note-BNF76-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-2"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).<span class="mw-ref" id="cite_ref-AHFS2019_5-4"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


<p>Adalimumab was approved for medical use in the United States in 2002.<span class="mw-ref" id="cite_ref-FDA_approval_8-0"><a href="#cite_note-FDA_approval-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2019_5-5"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_9-0"><a href="#cite_note-WHO21st-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> It is available as a biosimilar medication.<span class="mw-ref" id="cite_ref-pmid31322440_10-0"><a href="#cite_note-pmid31322440-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> In 2017, it was the 169th most commonly prescribed medication in the United States, with more than three million prescriptions.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>Like other TNF inhibitors, it is an immunosuppressive medication, used to treat autoimmune diseases such as rheumatoid arthritis.<span class="mw-ref" id="cite_ref-Humira_FDA_label_3-1"><a href="#cite_note-Humira_FDA_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Imraldi_label_13-0"><a href="#cite_note-Imraldi_label-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>Adalimumab is administered by subcutaneous injection.<span class="mw-ref" id="cite_ref-AHFS2019_5-6"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Humira_FDA_label_3-2"><a href="#cite_note-Humira_FDA_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> For most indications, the maintenance treatment is an injection every other week.<span class="mw-ref" id="cite_ref-AHFS2019_5-7"><a href="#cite_note-AHFS2019-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-Humira_FDA_label_3-3"><a href="#cite_note-Humira_FDA_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-Humira_EPAR_4-1"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>In the US, adalimumab is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult crohn's disease, pediatric crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.<span class="mw-ref" id="cite_ref-Humira_FDA_label_3-4"><a href="#cite_note-Humira_FDA_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<p>In the EU it is indicated for the treatment of:</p>
<ul><li>plaque psoriasis (a disease causing red, scaly patches on the skin);<span class="mw-ref" id="cite_ref-Humira_EPAR_4-2"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>psoriatic arthritis (a disease causing red, scaly patches on the skin with inflammation of the joints);<span class="mw-ref" id="cite_ref-Humira_EPAR_4-3"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>rheumatoid arthritis (a disease causing inflammation of the joints);<span class="mw-ref" id="cite_ref-Humira_EPAR_4-4"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>axial spondyloarthritis (inflammation of the spine causing back pain), including ankylosing spondylitis and when X-ray does not show disease but there are clear signs of inflammation;<span class="mw-ref" id="cite_ref-Humira_EPAR_4-5"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>polyarticular juvenile idiopathic arthritis and active enthesitis-related arthritis (both rare diseases causing inflammation in the joints);<span class="mw-ref" id="cite_ref-Humira_EPAR_4-6"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>Crohn’s disease (a disease causing inflammation of the gut);<span class="mw-ref" id="cite_ref-Humira_EPAR_4-7"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut);<span class="mw-ref" id="cite_ref-Humira_EPAR_4-8"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>hidradenitis suppurativa (acne inversa), a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin;<span class="mw-ref" id="cite_ref-Humira_EPAR_4-9"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li>
<li>non-infectious uveitis (inflammation of the layer beneath the white of the eyeball).<span class="mw-ref" id="cite_ref-Humira_EPAR_4-10"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></li></ul>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Rheumatoid_arthritis">Rheumatoid arthritis</h3></summary>
    
<p>Adalimumab has been shown to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults. It may be used alone or in combination with disease-modifying antirheumatic drugs (DMARD).<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> It has also been shown to have efficacy in moderate to severe polyarticular juvenile idiopathic arthritis in children four years and older, and is indicated for the treatment of that condition. In rheumatoid athritis, it is indicated for use alone, or with <a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">methotrexate</a> or similar medicines, in the United States since 2002.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span> It has a similar effectiveness as <a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">methotrexate</a> and, in combination, nearly doubles the response rate of methotrexate alone.<span class="mw-ref" id="cite_ref-AAFP_16-0"><a href="#cite_note-AAFP-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Psoriatic_arthritis">Psoriatic arthritis</h3></summary>
    
<p>In 2003, adalimumab began undergoing trials for use in treating psoriasis and psoriatic arthritis.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Ankylosing_spondylitis">Ankylosing spondylitis</h3></summary>
    

<p>Adalimumab has been shown to reduce the signs and symptoms of, and is approved for treatment of, ankylosing spondylitis in adults.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Crohn's_disease">Crohn's disease</h3></summary>
    

<p>Adalimumab has been shown to reduce the signs and symptoms of moderate to severe Crohn's disease.<span class="mw-ref" id="cite_ref-Podolsky_19-0"><a href="#cite_note-Podolsky-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-pmid31322440_10-1"><a href="#cite_note-pmid31322440-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> It has been approved for that use in the UK since 2009.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Ulcerative_colitis">Ulcerative colitis</h3></summary>
    

<p>Adalimumab may be effective and well tolerated in ulcerative colitis. It was approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe cases in adults.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Plaque_psoriasis">Plaque psoriasis</h3></summary>
    

<p>Adalimumab has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Hidradenitis_suppurativa">Hidradenitis suppurativa</h3></summary>
    

<p>Adalimumab was approved for hidradenitis suppurativa in 2015.<span class="mw-ref" id="cite_ref-hidradenitis_suppurativa_7-1"><a href="#cite_note-hidradenitis_suppurativa-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Juvenile_idiopathic_arthritis">Juvenile idiopathic arthritis</h3></summary>
    

<p>Adalimumab has been shown to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children aged four years and older.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Non-infectious_uveitis">Non-infectious uveitis</h3></summary>
    

<p>Adalimumab is indicated for the treatment of non-infectious uveitis (inflammation of the layer beneath the white of the eyeball).<span class="mw-ref" id="cite_ref-Humira_EPAR_4-11"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-Humira_FDA_label_3-5"><a href="#cite_note-Humira_FDA_label-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Components_of_an_Adalimumab-Humira_pen_-_annotated.jpg" tppabs="https://ptable.com/wiki/compounds/I/m/Components_of_an_Adalimumab-Humira_pen_-_annotated.jpg" data-file-width="654" data-file-height="1066" data-file-type="bitmap" height="359" width="220"><div class="thumbcaption" style="text-align: left">Components of a Humira autoinjector pen.</div></div></div>
<p>There is strong evidence that adalimumab increases risk of serious infections, such as tuberculosis. It also increases the risk of cancers, including lymphoma and solid malignancies. The risk of cancer is higher with higher doses of adalimumab.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span></p>

<p>There are rare reports of serious liver injury; rare reports of demyelinating central nervous system disorders; and rare reports of cardiac failure—the US Food and Drug Administration (FDA) issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully.<span class="mw-ref" id="cite_ref-medguide_32-0"><a href="#cite_note-medguide-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> Anaphylaxis or other serious allergic reactions may also occur.<span class="mw-ref" id="cite_ref-medguide_32-1"><a href="#cite_note-medguide-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA).<span class="mw-ref" id="cite_ref-pmid27416017_33-0"><a href="#cite_note-pmid27416017-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> It was derived from phage display.<span class="mw-ref" id="cite_ref-34"><a href="#cite_note-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span><span class="mw-ref" id="cite_ref-pmid27416017_33-1"><a href="#cite_note-pmid27416017-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>

<p>Adalimumab was discovered as a result of a collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology, U.K., itself a collaboration of the government-funded Medical Research Council and three academics, which began in 1993.<span class="mw-ref" id="cite_ref-35"><a href="#cite_note-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span><span class="mw-ref" id="cite_ref-36"><a href="#cite_note-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span><span class="mw-ref" id="cite_ref-pmid27416017_33-2"><a href="#cite_note-pmid27416017-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>

<p>Initially named D2E7,<span class="mw-ref" id="cite_ref-Kempeni99_37-0"><a href="#cite_note-Kempeni99-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> it was then further manufactured at BASF Bioresearch Corporation, developed by BASF Knoll (BASF Pharma), and ultimately manufactured and marketed by Abbott Laboratories after Abbott's acquisition of BASF Pharma. On 1 January 2013, Abbott split into two companies, one retaining the Abbott name and the other named AbbVie.<span class="mw-ref" id="cite_ref-AbbVie_38-0"><a href="#cite_note-AbbVie-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span> As a result, AbbVie took over development and marketing of Humira.<span class="mw-ref" id="cite_ref-PT_Humira_39-0"><a href="#cite_note-PT_Humira-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-40"><a href="#cite_note-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> The brand name Humira stands for "<b>hu</b>man <b>m</b>onoclonal antibody <b>i</b>n <b>r</b>heumatoid <b>a</b>rthritis", and was named by one of Abbott's employees, Richard J. Karwoski, who was also responsible for leading the effort to get Humira approved by the FDA.</p>

<p>It was the third TNF inhibitor, after <a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">infliximab</a> and <a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">etanercept</a>, to be approved in the United States.<span class="mw-ref" id="cite_ref-pmid27416017_33-3"><a href="#cite_note-pmid27416017-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span> It was constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein.</p>

<p>The drug candidate was discovered initially using CAT's phage display technology and named D2E7.<span class="mw-ref" id="cite_ref-Kempeni99_37-1"><a href="#cite_note-Kempeni99-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span> The key components of the drug were found by guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen TNF alpha.<span class="mw-ref" id="cite_ref-41"><a href="#cite_note-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> The ultimate clinical candidate, D2E7, was created and manufactured at BASF Bioresearch Corporation and taken through most of the drug development process by BASF Knoll, then further development, manufacturing and marketing by Abbott Laboratories, after Abbott acquired the pharmaceutical arm of BASF Knoll.<span class="mw-ref" id="cite_ref-42"><a href="#cite_note-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>

<p>Since 2008, adalimumab had been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012, by the FDA in the disease's management, it had been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's disease.</p>

<p>Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002.<span class="mw-ref" id="cite_ref-FDA_approval_8-1"><a href="#cite_note-FDA_approval-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-FDA_Humira_43-0"><a href="#cite_note-FDA_Humira-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span></p>

<p>Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003.<span class="mw-ref" id="cite_ref-Humira_EPAR_4-12"><a href="#cite_note-Humira_EPAR-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-44"><a href="#cite_note-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Marketing">Marketing</h3></summary>
    
<ul><li>1999: Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7<span class="mw-ref" id="cite_ref-Kempeni99_37-2"><a href="#cite_note-Kempeni99-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span></li>
<li>2001, June: Results from ARMADA, a double-blind, placebo-controlled clinical trial involving 271 patients with active rheumatoid arthritis despite treatment with methotrexate are announced.  Among the results are that 50% of patients show a 50% improvement in American College of Rheumatology (ACR) score.<span class="mw-ref" id="cite_ref-45"><a href="#cite_note-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span></li>
<li>2002: Broke ground on a new state-of-the-art biologics manufacturing facility.<span class="mw-ref" id="cite_ref-abbott.com_46-0"><a href="#cite_note-abbott.com-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></li>
<li>2002: Adalimumab results from five separate trials show that it is effective at reducing signs and symptoms of rheumatoid arthritis. In these studies, adalimumab had a rapid onset of action and sustained efficacy. Furthermore, adalimumab was safe and effective when given alone or in combination with MTX as a subcutaneous injection.<span class="mw-ref" id="cite_ref-47"><a href="#cite_note-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span></li>
<li>2002, 31 December: Humira approved by the US Food and Drug Administration (FDA) for treatment of rheumatoid arthritis.<span class="mw-ref" id="cite_ref-abbott.com_46-1"><a href="#cite_note-abbott.com-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></li>
<li>2003: Launched Humira for rheumatoid arthritis and continued clinical studies for additional indications.<span class="mw-ref" id="cite_ref-abbott.com_46-2"><a href="#cite_note-abbott.com-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></li>
<li>2005: Launched Humira for psoriatic arthritis. Exceeded <span style="white-space: nowrap">US$1<span class="nowrap"><span>&nbsp;</span></span>billion</span> in annual sales for the first time.<span class="mw-ref" id="cite_ref-abbott.com_46-3"><a href="#cite_note-abbott.com-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></li>
<li>2005: Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan.<span class="mw-ref" id="cite_ref-48"><a href="#cite_note-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span></li>
<li>2006: Submitted Humira for the Crohn's disease indication and launched it for AS. Exceeded <span style="white-space: nowrap">US$2<span class="nowrap"><span>&nbsp;</span></span>billion</span> in annual sales.<span class="mw-ref" id="cite_ref-abbott.com_46-4"><a href="#cite_note-abbott.com-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></li>
<li>2007: Launched Humira for Crohn's disease in the United States,<span class="mw-ref" id="cite_ref-abbott.com_46-5"><a href="#cite_note-abbott.com-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span> submitted Humira for global regulatory approval for psoriasis — the fifth new Humira disease indication at this time, achieved more than <span style="white-space: nowrap">US$3<span class="nowrap"><span>&nbsp;</span></span>billion</span> in worldwide Humira sales.<span class="mw-ref" id="cite_ref-49"><a href="#cite_note-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span></li>
<li>2007: Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico<span class="mw-ref" id="cite_ref-50"><a href="#cite_note-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></li>
<li>2008: Launched Humira for plaque psoriasis<span class="mw-ref" id="cite_ref-51"><a href="#cite_note-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span></li>
<li>2009: Five-Year Data Demonstrate Initial Use of Humira Plus Methotrexate May Prevent Further Joint Damage in Early Rheumatoid Arthritis Patients <span class="mw-ref" id="cite_ref-52"><a href="#cite_note-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span><span class="mw-ref" id="cite_ref-53"><a href="#cite_note-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span></li>
<li>2012: Humira could be associated with a significant decrease in vascular inflammation, a major risk factor of cardiovascular disease <span class="mw-ref" id="cite_ref-54"><a href="#cite_note-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span></li>
<li>2013: Due to the split of Abbott, Humira rights are now owned by AbbVie.<span class="mw-ref" id="cite_ref-AbbVie_38-1"><a href="#cite_note-AbbVie-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span><span class="mw-ref" id="cite_ref-PT_Humira_39-1"><a href="#cite_note-PT_Humira-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span></li>
<li>2014: Humira recognized by IMS Health as the "world's best selling drug."<span class="mw-ref" id="cite_ref-ap201407_55-0"><a href="#cite_note-ap201407-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span></li>
<li>2014: In December 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia.<span class="mw-ref" id="cite_ref-Reut2014India_56-0"><a href="#cite_note-Reut2014India-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></li>
<li>2015: Launched Humira for moderate to severe hidradenitis suppurativa, an orphan indication. No other treatment has been rigorously tested and found to be safe and effective in treating this painful and scarring condition.<span class="mw-ref" id="cite_ref-hidradenitis_suppurativa_7-2"><a href="#cite_note-hidradenitis_suppurativa-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></li>
<li>2016: The best selling drugs list researched by Genetic Engineering &amp; Biotechnology News, published in March 2017, details that Humira occupied the <abbr><span>#</span></abbr><span>1</span> position for 2015 (<span style="white-space: nowrap">US$14.012<span class="nowrap"><span>&nbsp;</span></span>billion</span>) and 2016 (<span style="white-space: nowrap">US$16.078<span class="nowrap"><span>&nbsp;</span></span>billion</span>)<span class="mw-ref" id="cite_ref-57"><a href="#cite_note-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span></li>
<li>2017: AbbVie reports that Humira achieved <span style="white-space: nowrap">US$18.427<span class="nowrap"><span>&nbsp;</span></span>billion</span> of sales in 2017.<span class="mw-ref" id="cite_ref-58"><a href="#cite_note-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span></li></ul>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Economics">Economics</h3></summary>
    
<p>From 2012, until the US patent expiry in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had <span style="white-space: nowrap">US$16<span class="nowrap"><span>&nbsp;</span></span>billion</span> of global sales.<span class="mw-ref" id="cite_ref-59"><a href="#cite_note-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span></p>

<p>In 2014, a biosimilar came to market in India at a lower price compared to United States prices.<span class="mw-ref" id="cite_ref-Reut2014India_56-1"><a href="#cite_note-Reut2014India-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Royalty_litigation">Royalty litigation</h3></summary>
    
<p>In March 2003, Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" with Abbott Laboratories in the High Court of London. In November 2004, the trial began, and in December 2004, Justice Hugh Laddie ruled for CAT.</p>

<p>A short version of the full statement of the proceedings was released.<span class="mw-ref" id="cite_ref-60"><a href="#cite_note-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span> In it Justice Laddie remarked, "Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2% of the Net Sales was due. It should have calculated on the basis of the full royalty of just over 5% and should have paid and continued to pay CAT accordingly." Justice Laddie went on to observe "...that the construction advanced by Abbott does violence to the language of the agreements, renders them obscure and makes little or no commercial sense. For this reason CAT wins the action."<span class="mw-ref" id="cite_ref-61"><a href="#cite_note-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span></p>

<p>Abbott was required to pay CAT <span style="white-space: nowrap">US$255<span class="nowrap"><span>&nbsp;</span></span>million</span>, some of which was to be passed to its partners in development.<span class="mw-ref" id="cite_ref-62"><a href="#cite_note-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span> Of this sum, the Medical Research Council received <span style="white-space: nowrap">US$191<span class="nowrap"><span>&nbsp;</span></span>million</span>, and in addition, Abbott was asked to pay the MRC a further <span style="white-space: nowrap">US$7.5<span class="nowrap"><span>&nbsp;</span></span>million</span> over five years from 2006, providing that Humira remains on the market. The MRC also is to receive a further £5.1<span class="nowrap"><span>&nbsp;</span></span>million (sterling) in respect of past royalties.<span class="mw-ref" id="cite_ref-63"><a href="#cite_note-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Patent_litigation">Patent litigation</h3></summary>
    
<p>On 29 May 2009, Johnson &amp; Johnson's Centocor unit, the maker of infliximab, won a ruling for $1.67<span class="nowrap"><span>&nbsp;</span></span>billion from Abbott Laboratories for patent infringement on the process for making Humira.<span class="mw-ref" id="cite_ref-64"><a href="#cite_note-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> However, in 2011, the judgment was overturned by the United States Court of Appeals for the Federal Circuit.<span class="mw-ref" id="cite_ref-65"><a href="#cite_note-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span><span class="mw-ref" id="cite_ref-66"><a href="#cite_note-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span><span class="mw-ref" id="cite_ref-67"><a href="#cite_note-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Biosimilars">Biosimilars</h3></summary>
    


<p>In 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia.<span class="mw-ref" id="cite_ref-Reut2014India_56-2"><a href="#cite_note-Reut2014India-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span> In 2016, Indian drugmaker Torrent Pharmaceuticals launched its biosimilar for adalimumab, called Adfrar. It was the second generic biosimilar of adalimumab.<span class="mw-ref" id="cite_ref-business-standard.com_68-0"><a href="#cite_note-business-standard.com-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span></p>

<p>In 2016, the FDA approved Amgen's biosimilar adalimumab-atto, sold under the brand name Amjevita.<span class="mw-ref" id="cite_ref-69"><a href="#cite_note-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span><span class="mw-ref" id="cite_ref-70"><a href="#cite_note-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span><span class="mw-ref" id="cite_ref-71"><a href="#cite_note-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span> Amjevita won't be available in the US until at least February 2023.<span class="mw-ref" id="cite_ref-72"><a href="#cite_note-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span> In 2017, the FDA approved German pharmaceutical company Boehringer Ingelheim's biosimilar, Cyltezo.<span class="mw-ref" id="cite_ref-73"><a href="#cite_note-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span><span class="mw-ref" id="cite_ref-74"><a href="#cite_note-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span><span class="mw-ref" id="cite_ref-75"><a href="#cite_note-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span></p>

<p>In 2017, the biosimilars Amgevita,<span class="mw-ref" id="cite_ref-76"><a href="#cite_note-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span> Solymbic,<span class="mw-ref" id="cite_ref-77"><a href="#cite_note-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span> Imraldi,<span class="mw-ref" id="cite_ref-78"><a href="#cite_note-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span> and Cyltezo<span class="mw-ref" id="cite_ref-79"><a href="#cite_note-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> were approved for use in the European Union.</p>

<p>In 2018, the biosimilars Halimatoz,<span class="mw-ref" id="cite_ref-80"><a href="#cite_note-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> Hefiya,<span class="mw-ref" id="cite_ref-81"><a href="#cite_note-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span> Hyrimoz,<span class="mw-ref" id="cite_ref-82"><a href="#cite_note-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> and Hulio<span class="mw-ref" id="cite_ref-83"><a href="#cite_note-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> were approved for use in the European Union.</p>

<p>Adalimumab biosimilars became available in Europe in late 2018,<span class="mw-ref" id="cite_ref-BPR-oct-2018_84-0"><a href="#cite_note-BPR-oct-2018-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span> allowing the National Health Service to make record-breaking cost-savings,<span class="mw-ref" id="cite_ref-85"><a href="#cite_note-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span> as this is the single most expensive drug used in NHS hospitals, costing more than £400<span class="nowrap"><span>&nbsp;</span></span>million a year for about 46,000 patients.<span class="mw-ref" id="cite_ref-86"><a href="#cite_note-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span> It may not become available in the United States until 2023.<span class="mw-ref" id="cite_ref-BPR-oct-2018_84-1"><a href="#cite_note-BPR-oct-2018-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span><span class="mw-ref" id="cite_ref-87"><a href="#cite_note-87" style="counter-reset: mw-Ref 87;"><span class="mw-reflink-text">[87]</span></a></span></p>

<p>In 2018, adalimumab-adaz (Hyrimoz) was approved for use in the United States.<span class="mw-ref" id="cite_ref-88"><a href="#cite_note-88" style="counter-reset: mw-Ref 88;"><span class="mw-reflink-text">[88]</span></a></span><span class="mw-ref" id="cite_ref-89"><a href="#cite_note-89" style="counter-reset: mw-Ref 89;"><span class="mw-reflink-text">[89]</span></a></span></p>

<p>In April 2019, Idacio<span class="mw-ref" id="cite_ref-90"><a href="#cite_note-90" style="counter-reset: mw-Ref 90;"><span class="mw-reflink-text">[90]</span></a></span> and Kromeya<span class="mw-ref" id="cite_ref-91"><a href="#cite_note-91" style="counter-reset: mw-Ref 91;"><span class="mw-reflink-text">[91]</span></a></span> were approved for use in the European Union.</p>

<p>In July 2019, adalimumab-bwwd (Hadlima), produced by Samsung Bioepsis, was approved for use in the US.<span class="mw-ref" id="cite_ref-92"><a href="#cite_note-92" style="counter-reset: mw-Ref 92;"><span class="mw-reflink-text">[92]</span></a></span><span class="mw-ref" id="cite_ref-93"><a href="#cite_note-93" style="counter-reset: mw-Ref 93;"><span class="mw-reflink-text">[93]</span></a></span> However, it will not be available until at least June 2023, after the availability of Amgen's offering as a result of a negotiated intellectual property settlement with AbbVie.<span class="mw-ref" id="cite_ref-94"><a href="#cite_note-94" style="counter-reset: mw-Ref 94;"><span class="mw-reflink-text">[94]</span></a></span></p>

<p>In November 2019, adalimumab-afzb (Abrilada) was approved for use in the United States.<span class="mw-ref" id="cite_ref-95"><a href="#cite_note-95" style="counter-reset: mw-Ref 95;"><span class="mw-reflink-text">[95]</span></a></span><span class="mw-ref" id="cite_ref-96"><a href="#cite_note-96" style="counter-reset: mw-Ref 96;"><span class="mw-reflink-text">[96]</span></a></span> It was the 25th biosimilar to be approved by the FDA.<span class="mw-ref" id="cite_ref-97"><a href="#cite_note-97" style="counter-reset: mw-Ref 97;"><span class="mw-reflink-text">[97]</span></a></span></p>

<p>In February 2020, the biosimilar Amsparity was approved for use in the European Union.<span class="mw-ref" id="cite_ref-98"><a href="#cite_note-98" style="counter-reset: mw-Ref 98;"><span class="mw-reflink-text">[98]</span></a></span></p>

<p>In July 2020, adalimumab-fkjp (Hulio) was approved for use in the United States.<span class="mw-ref" id="cite_ref-99"><a href="#cite_note-99" style="counter-reset: mw-Ref 99;"><span class="mw-reflink-text">[99]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Similar_agents">Similar agents</h2></summary>
    
<ul><li>Certolizumab pegol</li>
<li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/adalimumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/adalimumab.html'" tppabs="https://www.drugs.com/pregnancy/adalimumab.html" class="external text external">"Adalimumab Pregnancy and Breastfeeding Warnings"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">19 March</span> 2019</span>.</cite></span></li><li id="cite_note-Humira_SmPC-2"> <span id="mw-reference-text-cite_note-Humira_SmPC-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medicines.org.uk/emc/product/2150/smpc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medicines.org.uk/emc/product/2150/smpc'" tppabs="https://www.medicines.org.uk/emc/product/2150/smpc" class="external text external">"Humira 40 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)"</a>. <i>(emc)</i>. 27 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">12 August</span> 2020</span>.</cite></span></li><li id="cite_note-Humira_FDA_label-3"> <span id="mw-reference-text-cite_note-Humira_FDA_label-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d#section-1'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=608d4f0d-b19f-46d3-749a-7159aa5f933d#section-1" class="external text external">"Humira- adalimumab kit Humira- adalimumab injection, solution"</a>. <i>DailyMed</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-Humira_EPAR-4"> <span id="mw-reference-text-cite_note-Humira_EPAR-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/humira  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/humira'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/humira" class="external text external">"Humira EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite> Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span></li><li id="cite_note-AHFS2019-5"> <span id="mw-reference-text-cite_note-AHFS2019-5" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/adalimumab.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/adalimumab.html'" tppabs="https://www.drugs.com/monograph/adalimumab.html" class="external text external">"Adalimumab Monograph for Professionals"</a>. <i>Drugs.com</i>. American Society of Health-System Pharmacists. 14 May 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">18 March</span> 2019</span>.</cite></span></li><li id="cite_note-BNF76-6"> <span id="mw-reference-text-cite_note-BNF76-6" class="mw-reference-text"><cite class="citation book cs1"><i>British national formulary: BNF 76</i> (76 ed.). Pharmaceutical Press. 2018. p.<span>&nbsp;</span>1074. ISBN<span>&nbsp;</span><bdi>9780857113382</bdi>.</cite></span></li><li id="cite_note-hidradenitis_suppurativa-7"> <span id="mw-reference-text-cite_note-hidradenitis_suppurativa-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.medscape.com/viewarticle/850897  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.medscape.com/viewarticle/850897'" tppabs="https://www.medscape.com/viewarticle/850897" class="external text external">"FDA Clears Adalimumab (Humira) for Hidradenitis Suppurativa"</a>. Medscape. 11 September 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">13 October</span> 2017</span>.</cite></span></li><li id="cite_note-FDA_approval-8"> <span id="mw-reference-text-cite_note-FDA_approval-8" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/125057_toc.cfm" class="external text external">"Drug Approval Package: Humira (adalimumab)"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 7 April 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-WHO21st-9"> <span id="mw-reference-text-cite_note-WHO21st-9" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-pmid31322440-10"> <span id="mw-reference-text-cite_note-pmid31322440-10" class="mw-reference-text"><cite id="CITEREFPeyrin-BirouletDaneseCummingsAtreya2019" class="citation journal cs1">Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B,  et al. (26 July 2019). <a href="javascript:if(confirm('https://doi.org/10.1080/17474124.2019.1645595  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080/17474124.2019.1645595'" tppabs="https://doi.org/10.1080/17474124.2019.1645595" class="external text external">"Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach"</a>. <i>Expert Review of Gastroenterology &amp; Hepatology</i>. <b>13</b> (8): 731–738. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1080%2F17474124.2019.1645595  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F17474124.2019.1645595'" tppabs="https://doi.org/10.1080%2F17474124.2019.1645595" class="external text external">10.1080/17474124.2019.1645595</a></span>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1747-4124  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1747-4124'" tppabs="https://www.worldcat.org/issn/1747-4124" class="external text external">1747-4124</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31322440  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31322440'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31322440" class="external text external">31322440</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Top300Drugs.aspx  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Top300Drugs.aspx'" tppabs="https://clincalc.com/DrugStats/Top300Drugs.aspx" class="external text external">"The Top 300 of 2020"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://clincalc.com/DrugStats/Drugs/Adalimumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://clincalc.com/DrugStats/Drugs/Adalimumab'" tppabs="https://clincalc.com/DrugStats/Drugs/Adalimumab" class="external text external">"Adalimumab - Drug Usage Statistics"</a>. <i>ClinCalc</i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2020</span>.</cite></span></li><li id="cite_note-Imraldi_label-13"> <span id="mw-reference-text-cite_note-Imraldi_label-13" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdfaa71-27ed-4717-8e7d-f1a5fe0d1fa6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdfaa71-27ed-4717-8e7d-f1a5fe0d1fa6'" tppabs="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acdfaa71-27ed-4717-8e7d-f1a5fe0d1fa6" class="external text external">"Imraldi- adalimumab injection, solution"</a>. <i>DailyMed</i>. 23 January 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFNavarro-SarabiaAriza-ArizaHernandez-CruzVillanueva2005" class="citation journal cs1">Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (20 July 2005). <a href="javascript:if(confirm('https://doi.org/10.1002/14651858.CD005113.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002/14651858.CD005113.pub2'" tppabs="https://doi.org/10.1002/14651858.CD005113.pub2" class="external text external">"Adalimumab for treating rheumatoid arthritis"</a>. <i>The Cochrane Database of Systematic Reviews</i> (3): CD005113. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD005113.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD005113.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD005113.pub2" class="external text external">10.1002/14651858.CD005113.pub2</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16034967  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16034967'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16034967" class="external text external">16034967</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFSiegel" class="citation web cs1">Siegel JP. <a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/adalabb123102L.htm" class="external text external">"Product Approval Information - Licensing Action"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 February</span> 2014</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-AAFP-16"> <span id="mw-reference-text-cite_note-AAFP-16" class="mw-reference-text"><cite id="CITEREFWelch2008" class="citation journal cs1">Welch B (15 December 2008). <a href="javascript:if(confirm('http://www.aafp.org/afp/2008/1215/p1406.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.aafp.org/afp/2008/1215/p1406.html'" tppabs="http://www.aafp.org/afp/2008/1215/p1406.html" class="external text external">"Adalimumab (Humira) for the Treatment of Rheumatoid Arthritis"</a>. <i>American Family Physician</i>. <b>78</b> (12): 1406–1408. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0002-838X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0002-838X'" tppabs="https://www.worldcat.org/issn/0002-838X" class="external text external">0002-838X</a><span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite id="CITEREFScheinfeld2003" class="citation journal cs1">Scheinfeld N (2003). "Adalimumab (Humira): a review". <i>J Drugs Dermatol</i>. <b>2</b> (4): 375–7. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12884458  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12884458'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12884458" class="external text external">12884458</a>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFMaxwellZochlingBoonenSingh2015" class="citation journal cs1">Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E,  et al. (18 April 2015). <a href="javascript:if(confirm('http://ecite.utas.edu.au/120128  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://ecite.utas.edu.au/120128'" tppabs="http://ecite.utas.edu.au/120128" class="external text external">"TNF-alpha inhibitors for ankylosing spondylitis"</a>. <i>The Cochrane Database of Systematic Reviews</i>. <b>4</b> (4): CD005468. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD005468.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD005468.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD005468.pub2" class="external text external">10.1002/14651858.CD005468.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25887212  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25887212'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25887212" class="external text external">25887212</a>.</cite></span></li><li id="cite_note-Podolsky-19"> <span id="mw-reference-text-cite_note-Podolsky-19" class="mw-reference-text"><cite id="CITEREFPodolsky2002" class="citation journal cs1">Podolsky DK (August 2002). <a href="javascript:if(confirm('https://gut.bmj.com/content/gutjnl/39/Suppl_1/A15.full.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://gut.bmj.com/content/gutjnl/39/Suppl_1/A15.full.pdf'" tppabs="https://gut.bmj.com/content/gutjnl/39/Suppl_1/A15.full.pdf" class="external text external">"Inflammatory bowel disease"</a> <span class="cs1-format">(PDF)</span>. <i>N Engl J Med</i>. <b>347</b> (6): 417–29. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMra020831  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMra020831'" tppabs="https://doi.org/10.1056%2FNEJMra020831" class="external text external">10.1056/NEJMra020831</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12167685  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12167685'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12167685" class="external text external">12167685</a>.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFGearryFramptonInnsPoppelwell2019" class="citation journal cs1">Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R (3 July 2019). "VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand". <i>Current Medical Research and Opinion</i>. <b>35</b> (10): 1837–1846. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F03007995.2019.1634952  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F03007995.2019.1634952'" tppabs="https://doi.org/10.1080%2F03007995.2019.1634952" class="external text external">10.1080/03007995.2019.1634952</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0300-7995  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0300-7995'" tppabs="https://www.worldcat.org/issn/0300-7995" class="external text external">0300-7995</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31233347  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31233347'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31233347" class="external text external">31233347</a>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFMorey2009" class="citation web cs1">Morey S (17 September 2009). <a href="javascript:if(confirm('https://worldpharmaoutlook.blogspot.com/2009/09/uk-summary-of-nice-approvals-in.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://worldpharmaoutlook.blogspot.com/2009/09/uk-summary-of-nice-approvals-in.html'" tppabs="https://worldpharmaoutlook.blogspot.com/2009/09/uk-summary-of-nice-approvals-in.html" class="external text external">"UK – Summary of NICE Approvals in September 2009"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">4 February</span> 2014</span>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20120930235859/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20120930235859/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm'" tppabs="https://web.archive.org/web/20120930235859/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm" class="external text external">"FDA approves Humira to treat ulcerative colitis"</a> (Press release). U.S. Food and Drug Administration (FDA). 28 September 2012. Archived from <a href="javascript:if(confirm('https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm'" tppabs="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm321650.htm" class="external text external">the original</a> on 30 September 2012.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis'" tppabs="https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis" class="external text external">"Abbott's Humira (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis"</a>. <i>Abbott</i> (Press release). 28 September 2012. <a href="javascript:if(confirm('https://web.archive.org/web/20191119023917/https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191119023917/https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis'" tppabs="https://web.archive.org/web/20191119023917/https://abbott.mediaroom.com/2012-09-28-Abbotts-HUMIRA-adalimumab-Receives-U-S-FDA-Approval-for-the-Treatment-of-Adult-Patients-with-Moderate-to-Severe-Ulcerative-Colitis" class="external text external">Archived</a> from the original on 19 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 November</span> 2019</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite id="CITEREFCroomMcCormack2009" class="citation journal cs1">Croom KF, McCormack PL (2009). "Adalimumab". <i>Am J Clin Dermatol</i>. <b>10</b> (1): 43–50. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F0128071-200910010-00008  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F0128071-200910010-00008'" tppabs="https://doi.org/10.2165%2F0128071-200910010-00008" class="external text external">10.2165/0128071-200910010-00008</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19170412  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19170412'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19170412" class="external text external">19170412</a>.</cite></span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFMenterTyringGordonKimball2008" class="citation journal cs1">Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K (January 2008). "Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial". <i>J. Am. Acad. Dermatol</i>. <b>58</b> (1): 106–15. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jaad.2007.09.010  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jaad.2007.09.010'" tppabs="https://doi.org/10.1016%2Fj.jaad.2007.09.010" class="external text external">10.1016/j.jaad.2007.09.010</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17936411  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17936411'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17936411" class="external text external">17936411</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFGulliverZouboulisPrensJemec2016" class="citation journal cs1">Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T (September 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156664'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156664" class="external text external">"Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa"</a>. <i>Rev Endocr Metab Disord</i>. <b>17</b> (3): 343–351. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11154-016-9328-5  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11154-016-9328-5'" tppabs="https://doi.org/10.1007%2Fs11154-016-9328-5" class="external text external">10.1007/s11154-016-9328-5</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156664'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5156664" class="external text external">5156664</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/26831295  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/26831295'" tppabs="https://pubmed.ncbi.nlm.nih.gov/26831295" class="external text external">26831295</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFMaaroufClarkLeeShi2018" class="citation journal cs1">Maarouf M, Clark AK, Lee DE, Shi VY (August 2018). "Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials". <i>J Dermatolog Treat</i>. <b>29</b> (5): 441–449. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F09546634.2017.1395806  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F09546634.2017.1395806'" tppabs="https://doi.org/10.1080%2F09546634.2017.1395806" class="external text external">10.1080/09546634.2017.1395806</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29098911  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29098911'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29098911" class="external text external">29098911</a>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite id="CITEREFBrunnerNandaTothFoeldvari2019" class="citation journal cs1">Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D, Rabinovich CE, Kingsbury DJ, Marzan K, Chalom E, Horneff G, Kuester RM, Dare JA, Trachana M, Jung LK, Olson J, Minden K, Quartier P, Bereswill M, Kalabic J, Kupper H, Lovell DJ, Martini A, Ruperto N (August 2019). <a href="javascript:if(confirm('https://doi.org/10.1002/acr.24044  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002/acr.24044'" tppabs="https://doi.org/10.1002/acr.24044" class="external text external">"Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry 7-Year Interim Results"</a>. <i>Arthritis Care Res (Hoboken)</i>. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1002%2Facr.24044  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Facr.24044'" tppabs="https://doi.org/10.1002%2Facr.24044" class="external text external">10.1002/acr.24044</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/31421019  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/31421019'" tppabs="https://pubmed.ncbi.nlm.nih.gov/31421019" class="external text external">31421019</a>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFHorneffSeygerArikanKalabic2018" class="citation journal cs1">Horneff G, Seyger MM, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS (October 2018). <a href="javascript:if(confirm('https://doi.org/10.1016/j.jpeds.2018.05.042  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016/j.jpeds.2018.05.042'" tppabs="https://doi.org/10.1016/j.jpeds.2018.05.042" class="external text external">"Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease"</a>. <i>J. Pediatr</i>. <b>201</b>: 166–175.e3. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.jpeds.2018.05.042  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.jpeds.2018.05.042'" tppabs="https://doi.org/10.1016%2Fj.jpeds.2018.05.042" class="external text external">10.1016/j.jpeds.2018.05.042</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/30054164  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/30054164'" tppabs="https://pubmed.ncbi.nlm.nih.gov/30054164" class="external text external">30054164</a>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite id="CITEREFCorrellBullockCaffertyVehe2018" class="citation journal cs1">Correll CK, Bullock DR, Cafferty RM, Vehe RK (February 2018). "Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis". <i>Clin. Rheumatol</i>. <b>37</b> (2): 549–553. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10067-017-3890-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10067-017-3890-4'" tppabs="https://doi.org/10.1007%2Fs10067-017-3890-4" class="external text external">10.1007/s10067-017-3890-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/29103180  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/29103180'" tppabs="https://pubmed.ncbi.nlm.nih.gov/29103180" class="external text external">29103180</a>.</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite id="CITEREFHochmanWolff2006" class="citation journal cs1">Hochman D, Wolff B (November 2006). "Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis". <i>JAMA</i>. <b>296</b> (18): 2203, author reply 2203–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.296.18.2203-a  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.296.18.2203-a'" tppabs="https://doi.org/10.1001%2Fjama.296.18.2203-a" class="external text external">10.1001/jama.296.18.2203-a</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17090763  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17090763'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17090763" class="external text external">17090763</a>.</cite></span></li><li id="cite_note-medguide-32"> <span id="mw-reference-text-cite_note-medguide-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.rxabbott.com/pdf/humira_medguide.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.rxabbott.com/pdf/humira_medguide.pdf'" tppabs="http://www.rxabbott.com/pdf/humira_medguide.pdf" class="external text external">"Humira Medication Guide"</a> <span class="cs1-format">(PDF)</span>. October 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-pmid27416017-33"> <span id="mw-reference-text-cite_note-pmid27416017-33" class="mw-reference-text"><cite id="CITEREFFrenzelSchirrmannHust2016" class="citation journal cs1">Frenzel A, Schirrmann T, Hust M (October 2016). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633" class="external text external">"Phage display-derived human antibodies in clinical development and therapy"</a>. <i>MAbs</i>. <b>8</b> (7): 1177–94. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1080%2F19420862.2016.1212149  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F19420862.2016.1212149'" tppabs="https://doi.org/10.1080%2F19420862.2016.1212149" class="external text external">10.1080/19420862.2016.1212149</a></span>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058633" class="external text external">5058633</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27416017  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27416017'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27416017" class="external text external">27416017</a>.</cite></span></li><li id="cite_note-34"> <span id="mw-reference-text-cite_note-34" class="mw-reference-text"><cite id="CITEREFBrekkeSandlie2003" class="citation journal cs1">Brekke OH, Sandlie I (January 2003). "Therapeutic antibodies for human diseases at the dawn of the twenty-first century". <i>Nat Rev Drug Discov</i>. <b>2</b> (1): 52–62. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnrd984  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnrd984'" tppabs="https://doi.org/10.1038%2Fnrd984" class="external text external">10.1038/nrd984</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12509759  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12509759'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12509759" class="external text external">12509759</a>.</cite></span></li><li id="cite_note-35"> <span id="mw-reference-text-cite_note-35" class="mw-reference-text"><a href="javascript:if(confirm('http://www.cambridgeantibody.com/home/news_and_resources/news_archive/2003/cambridge_antibody_technology__humira  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cambridgeantibody.com/home/news_and_resources/news_archive/2003/cambridge_antibody_technology__humira'" tppabs="http://www.cambridgeantibody.com/home/news_and_resources/news_archive/2003/cambridge_antibody_technology__humira" class="external autonumber external"></a></span></li><li id="cite_note-36"> <span id="mw-reference-text-cite_note-36" class="mw-reference-text"><cite id="CITEREFMcCafferty2010" class="citation journal cs1">McCafferty J (2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958567  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958567'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958567" class="external text external">"The long and winding road to antibody therapeutics"</a>. <i>mAbs</i>. <b>2</b> (5): 459–460. doi:<a href="javascript:if(confirm('https://doi.org/10.4161%2Fmabs.2.5.13088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4161%2Fmabs.2.5.13088'" tppabs="https://doi.org/10.4161%2Fmabs.2.5.13088" class="external text external">10.4161/mabs.2.5.13088</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1942-0862  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1942-0862'" tppabs="https://www.worldcat.org/issn/1942-0862" class="external text external">1942-0862</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958567  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958567'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958567" class="external text external">2958567</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20978369  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20978369'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20978369" class="external text external">20978369</a>.</cite></span></li><li id="cite_note-Kempeni99-37"> <span id="mw-reference-text-cite_note-Kempeni99-37" class="mw-reference-text"><cite id="CITEREFKempeni1999" class="citation journal cs1">Kempeni J (January 1999). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766582  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766582'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766582" class="external text external">"Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7"</a>. <i>Ann Rheum Dis</i>. <b>58</b> (suppl 1): I70–2. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fard.58.2008.i70  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fard.58.2008.i70'" tppabs="https://doi.org/10.1136%2Fard.58.2008.i70" class="external text external">10.1136/ard.58.2008.i70</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766582  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766582'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766582" class="external text external">1766582</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10577977  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10577977'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10577977" class="external text external">10577977</a>.</cite></span></li><li id="cite_note-AbbVie-38"> <span id="mw-reference-text-cite_note-AbbVie-38" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.abbottinvestor.com/news-releases/news-release-details/abbott-completes-separation-research-based-pharmaceuticals/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.abbottinvestor.com/news-releases/news-release-details/abbott-completes-separation-research-based-pharmaceuticals/'" tppabs="https://www.abbottinvestor.com/news-releases/news-release-details/abbott-completes-separation-research-based-pharmaceuticals/" class="external text external">"Abbott Completes Separation Of Research-Based Pharmaceuticals Business"</a> (Press release). Abbott Laboratories.</cite></span></li><li id="cite_note-PT_Humira-39"> <span id="mw-reference-text-cite_note-PT_Humira-39" class="mw-reference-text"><cite id="CITEREFTurner2018" class="citation web cs1">Turner S (5 September 2018). <a href="javascript:if(confirm('https://www.pharmaceutical-technology.com/features/humira-abbvie-drug/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.pharmaceutical-technology.com/features/humira-abbvie-drug/'" tppabs="https://www.pharmaceutical-technology.com/features/humira-abbvie-drug/" class="external text external">"Humira: the highs and lows of the world's most successful drug"</a>. <i>Pharmaceutical Technology</i><span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-40"> <span id="mw-reference-text-cite_note-40" class="mw-reference-text"><cite id="CITEREFJapsen2019" class="citation web cs1">Japsen B (26 February 2019). <a href="javascript:if(confirm('https://www.forbes.com/sites/brucejapsen/2019/02/26/why-abbvie-may-have-a-tough-time-defending-humiras-price-before-congress/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.forbes.com/sites/brucejapsen/2019/02/26/why-abbvie-may-have-a-tough-time-defending-humiras-price-before-congress/'" tppabs="https://www.forbes.com/sites/brucejapsen/2019/02/26/why-abbvie-may-have-a-tough-time-defending-humiras-price-before-congress/" class="external text external">"Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-41"> <span id="mw-reference-text-cite_note-41" class="mw-reference-text"><cite id="CITEREFJespersRobertsMahlerWinter1994" class="citation journal cs1">Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR (September 1994). "Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen". <i>Bio/Technology</i>. <b>12</b> (9): 899–903. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fnbt0994-899  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fnbt0994-899'" tppabs="https://doi.org/10.1038%2Fnbt0994-899" class="external text external">10.1038/nbt0994-899</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7521646  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7521646'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7521646" class="external text external">7521646</a>.</cite></span></li><li id="cite_note-42"> <span id="mw-reference-text-cite_note-42" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20130212013858/http://www2.basf.us/corporate/news2000/newsknoll_pharma_121500.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20130212013858/http://www2.basf.us/corporate/news2000/newsknoll_pharma_121500.html'" tppabs="https://web.archive.org/web/20130212013858/http://www2.basf.us/corporate/news2000/newsknoll_pharma_121500.html" class="external text external">"BASF to focus more strongly on innovative chemistry, a highly efficient Verbund and a global presence"</a> (Press release). Archived from <a href="javascript:if(confirm('http://www2.basf.us/corporate/news2000/newsknoll_pharma_121500.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www2.basf.us/corporate/news2000/newsknoll_pharma_121500.html'" tppabs="http://www2.basf.us/corporate/news2000/newsknoll_pharma_121500.html" class="external text external">the original</a> on 12 February 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">9 December</span> 2012</span>.</cite></span></li><li id="cite_note-FDA_Humira-43"> <span id="mw-reference-text-cite_note-FDA_Humira-43" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125057  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125057'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125057" class="external text external">"Humira: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-44"> <span id="mw-reference-text-cite_note-44" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/trudexa  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/trudexa'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/trudexa" class="external text external">"Trudexa EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-45"> <span id="mw-reference-text-cite_note-45" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.abbottinvestor.com/news-releases/news-release-details/abbott-laboratories-investigational-fully-human-anti-tnf-therapy  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.abbottinvestor.com/news-releases/news-release-details/abbott-laboratories-investigational-fully-human-anti-tnf-therapy'" tppabs="https://www.abbottinvestor.com/news-releases/news-release-details/abbott-laboratories-investigational-fully-human-anti-tnf-therapy" class="external text external">"Abbott Laboratories' Investigational Fully Human Anti-Tnf Therapy, D2E7 (Adalimumab), Shows Promise In Reducing The Signs And Symptoms Of Rheumatoid Arthritis"</a> (Press release). 12 November 2001.</cite></span></li><li id="cite_note-abbott.com-46"> <span id="mw-reference-text-cite_note-abbott.com-46" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://truecostofhealthcare.org/wp-content/uploads/2015/01/Abbott_Report_2006.87103312.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://truecostofhealthcare.org/wp-content/uploads/2015/01/Abbott_Report_2006.87103312.pdf'" tppabs="http://truecostofhealthcare.org/wp-content/uploads/2015/01/Abbott_Report_2006.87103312.pdf" class="external text external">"Abbott 2006 Annual Report"</a> <span class="cs1-format">(PDF)</span>. Abbott. <a href="javascript:if(confirm('https://web.archive.org/web/20080113230332/http://www.abbott.com/static/content/microsite/annual_report/2006/humira.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20080113230332/http://www.abbott.com/static/content/microsite/annual_report/2006/humira.html'" tppabs="https://web.archive.org/web/20080113230332/http://www.abbott.com/static/content/microsite/annual_report/2006/humira.html" class="external text external">Archived</a> from the original on 13 January 2008<span class="reference-accessdate">. Retrieved <span class="nowrap">27 July</span> 2009</span>.</cite></span></li><li id="cite_note-47"> <span id="mw-reference-text-cite_note-47" class="mw-reference-text"><cite id="CITEREFRau2002" class="citation journal cs1">Rau R (January 2002). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766697  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766697'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766697" class="external text external">"Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials"</a>. <i>Ann Rheum Dis</i>. <b>61</b> (Suppl 2): ii70–3. doi:<a href="javascript:if(confirm('https://doi.org/10.1136%2Fard.61.suppl_2.ii70  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1136%2Fard.61.suppl_2.ii70'" tppabs="https://doi.org/10.1136%2Fard.61.suppl_2.ii70" class="external text external">10.1136/ard.61.suppl_2.ii70</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766697  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766697'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766697" class="external text external">1766697</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12379628  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12379628'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12379628" class="external text external">12379628</a>.</cite></span></li><li id="cite_note-48"> <span id="mw-reference-text-cite_note-48" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.thefreelibrary.com/Eisai+Submits+New+Drug+Application+for+Rheumatoid+Arthritis+Drug...-a0140148456  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.thefreelibrary.com/Eisai+Submits+New+Drug+Application+for+Rheumatoid+Arthritis+Drug...-a0140148456'" tppabs="http://www.thefreelibrary.com/Eisai+Submits+New+Drug+Application+for+Rheumatoid+Arthritis+Drug...-a0140148456" class="external text external">"Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan"</a>. <i>thefreelibrary.com</i>.</cite></span></li><li id="cite_note-49"> <span id="mw-reference-text-cite_note-49" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://truecostofhealthcare.org/wp-content/uploads/2015/01/Abbott_Report_2007.87102217.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://truecostofhealthcare.org/wp-content/uploads/2015/01/Abbott_Report_2007.87102217.pdf'" tppabs="http://truecostofhealthcare.org/wp-content/uploads/2015/01/Abbott_Report_2007.87102217.pdf" class="external text external">"Abbott 2007 Annual Report"</a> <span class="cs1-format">(PDF)</span>. Abbott. <a href="javascript:if(confirm('https://web.archive.org/web/20090503120558/http://www.abbott.com/static/content/microsite/annual_report/2007/overview_milestones.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090503120558/http://www.abbott.com/static/content/microsite/annual_report/2007/overview_milestones.html'" tppabs="https://web.archive.org/web/20090503120558/http://www.abbott.com/static/content/microsite/annual_report/2007/overview_milestones.html" class="external text external">Archived</a> from the original on 3 May 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">27 July</span> 2009</span>.</cite></span></li><li id="cite_note-50"> <span id="mw-reference-text-cite_note-50" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.abbottinvestor.com/news-releases/news-release-details/abbott-opens-new-biotechnology-manufacturing-facility-puerto/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.abbottinvestor.com/news-releases/news-release-details/abbott-opens-new-biotechnology-manufacturing-facility-puerto/'" tppabs="https://www.abbottinvestor.com/news-releases/news-release-details/abbott-opens-new-biotechnology-manufacturing-facility-puerto/" class="external text external">"Abbott Opens New Biotechnology Manufacturing Facility In Puerto Rico"</a> (Press release). Abbott. 10 April 2007. <a href="javascript:if(confirm('https://web.archive.org/web/20090530074305/http://www.abbott.com/global/url/pressRelease/en_US/60.5%3A5/Press_Release_0439.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20090530074305/http://www.abbott.com/global/url/pressRelease/en_US/60.5%3A5/Press_Release_0439.htm'" tppabs="https://web.archive.org/web/20090530074305/http://www.abbott.com/global/url/pressRelease/en_US/60.5%3A5/Press_Release_0439.htm" class="external text external">Archived</a> from the original on 30 May 2009<span class="reference-accessdate">. Retrieved <span class="nowrap">27 July</span> 2009</span>.</cite></span></li><li id="cite_note-51"> <span id="mw-reference-text-cite_note-51" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.abbottinvestor.com/news-releases/news-release-details/abbotts-humirar-adalimumab-receives-fda-approval-moderate-severe  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.abbottinvestor.com/news-releases/news-release-details/abbotts-humirar-adalimumab-receives-fda-approval-moderate-severe'" tppabs="https://www.abbottinvestor.com/news-releases/news-release-details/abbotts-humirar-adalimumab-receives-fda-approval-moderate-severe" class="external text external">"Abbott's Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis"</a> (Press release). Abbott Laboratories. 18 January 2008<span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-52"> <span id="mw-reference-text-cite_note-52" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20100322234901/http://www.abbott.com/global/url/pressRelease/en_US/60.5%3A5/Press_Release_0737.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20100322234901/http://www.abbott.com/global/url/pressRelease/en_US/60.5%3A5/Press_Release_0737.htm'" tppabs="https://web.archive.org/web/20100322234901/http://www.abbott.com/global/url/pressRelease/en_US/60.5%3A5/Press_Release_0737.htm" class="external text external">"Five-Year Data Demonstrate Initial Use Of Abbott's Humira (Adalimumab) Plus Methotrexate May Prevent Further Joint Damage In Early Rheumatoid Arthritis Patients"</a> (Press release). Abbott. Archived from <a href="javascript:if(confirm('http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0737.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0737.htm'" tppabs="http://www.abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0737.htm" class="external text external">the original</a> on 22 March 2010<span class="reference-accessdate">. Retrieved <span class="nowrap">27 July</span> 2009</span>.</cite></span></li><li id="cite_note-53"> <span id="mw-reference-text-cite_note-53" class="mw-reference-text"><cite id="CITEREFPapagorasVoulgariDrosos2009" class="citation journal cs1">Papagoras C, Voulgari PV, Drosos AA (2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727" class="external text external">"Long-term use of adalimumab in the treatment of rheumatic diseases"</a>. <i>Open Access Rheumatology: Research and Reviews</i>. <b>1</b>: 51–68. doi:<a href="javascript:if(confirm('https://doi.org/10.2147%2Foarrr.s4297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2147%2Foarrr.s4297'" tppabs="https://doi.org/10.2147%2Foarrr.s4297" class="external text external">10.2147/oarrr.s4297</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1179-156X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1179-156X'" tppabs="https://www.worldcat.org/issn/1179-156X" class="external text external">1179-156X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727" class="external text external">5074727</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27789981  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27789981'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27789981" class="external text external">27789981</a>.</cite></span></li><li id="cite_note-54"> <span id="mw-reference-text-cite_note-54" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.sciencedaily.com/releases/2012/03/120316101632.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.sciencedaily.com/releases/2012/03/120316101632.htm'" tppabs="https://www.sciencedaily.com/releases/2012/03/120316101632.htm" class="external text external">"Treating psoriasis to prevent heart attacks and strokes"</a>. <i>ScienceDaily</i>.</cite></span></li><li id="cite_note-ap201407-55"> <span id="mw-reference-text-cite_note-ap201407-55" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20140727000006/http://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20140727000006/http://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2'" tppabs="https://web.archive.org/web/20140727000006/http://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2" class="external text external">"Humira Lifts AbbVie 2.8% in Q2"</a>. <i>Discovery and Development</i>. Associated Press. 25 July 2014. Archived from <a href="javascript:if(confirm('http://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2'" tppabs="http://www.dddmag.com/news/2014/07/humira-lifts-abbvie-28-q2" class="external text external">the original</a> on 27 July 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">27 July</span> 2014</span>.</cite></span></li><li id="cite_note-Reut2014India-56"> <span id="mw-reference-text-cite_note-Reut2014India-56" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.reuters.com/article/us-cadila-health-humira-india/indias-cadila-launches-first-cheaper-copy-of-worlds-top-selling-drug-idUSKBN0JN0X820141209  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/us-cadila-health-humira-india/indias-cadila-launches-first-cheaper-copy-of-worlds-top-selling-drug-idUSKBN0JN0X820141209'" tppabs="https://www.reuters.com/article/us-cadila-health-humira-india/indias-cadila-launches-first-cheaper-copy-of-worlds-top-selling-drug-idUSKBN0JN0X820141209" class="external text external">"India's Cadila launches first cheaper copy of world's top-selling drug"</a>. Reuters. 9 December 2014<span class="reference-accessdate">. Retrieved <span class="nowrap">19 March</span> 2019</span>.</cite></span></li><li id="cite_note-57"> <span id="mw-reference-text-cite_note-57" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868'" tppabs="https://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868" class="external text external">"The Top 15 Best-Selling Drugs of 2016 - The Lists - GEN"</a>. <i>Genengnews.com</i>.</cite></span></li><li id="cite_note-58"> <span id="mw-reference-text-cite_note-58" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results.htm'" tppabs="https://news.abbvie.com/news/abbvie-reports-full-year-and-fourth-quarter-2017-financial-results.htm" class="external text external">"AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results"</a>. <i>AbbVie</i> (Press release).</cite></span></li><li id="cite_note-59"> <span id="mw-reference-text-cite_note-59" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868'" tppabs="http://www.genengnews.com/the-lists/the-top-15-best-selling-drugs-of-2016/77900868" class="external text external">"The Top 15 Best-Selling Drugs of 2016 - The Lists - GEN Genetic Engineering &amp; Biotechnology News - Biotech from Bench to Business - GEN"</a>. <i>Genengnews.com</i>.</cite></span></li><li id="cite_note-60"> <span id="mw-reference-text-cite_note-60" class="mw-reference-text"><a href="javascript:if(confirm('http://www.chandb.com/MBE/assessment_041220_CaT_Abbott_judgement_summary.doc  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chandb.com/MBE/assessment_041220_CaT_Abbott_judgement_summary.doc'" tppabs="http://www.chandb.com/MBE/assessment_041220_CaT_Abbott_judgement_summary.doc" class="external autonumber external"></a></span></li><li id="cite_note-61"> <span id="mw-reference-text-cite_note-61" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://news.bbc.co.uk/1/hi/business/4112235.stm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://news.bbc.co.uk/1/hi/business/4112235.stm'" tppabs="http://news.bbc.co.uk/1/hi/business/4112235.stm" class="external text external">"Biotech firm wins royalty fight"</a>. <i>BBC News Online</i>. 20 December 2004<span class="reference-accessdate">. Retrieved <span class="nowrap">23 April</span> 2010</span>.</cite></span></li><li id="cite_note-62"> <span id="mw-reference-text-cite_note-62" class="mw-reference-text"><cite id="CITEREFMurray-West2005" class="citation news cs1">Murray-West R (27 October 2005). <a href="javascript:if(confirm('https://www.telegraph.co.uk/finance/2924694/Drug-maker-CAT-surges-after-royalty-settlement.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.telegraph.co.uk/finance/2924694/Drug-maker-CAT-surges-after-royalty-settlement.html'" tppabs="https://www.telegraph.co.uk/finance/2924694/Drug-maker-CAT-surges-after-royalty-settlement.html" class="external text external">"Drug maker CAT surges after royalty settlement"</a>. <i>The Telegraph</i>. London<span class="reference-accessdate">. Retrieved <span class="nowrap">23 April</span> 2010</span>.</cite></span></li><li id="cite_note-63"> <span id="mw-reference-text-cite_note-63" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20070627194553/http://www.mrctechnology.org/resources/PR/MRC_Humira_PRESS_RELEASE.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20070627194553/http://www.mrctechnology.org/resources/PR/MRC_Humira_PRESS_RELEASE.pdf'" tppabs="https://web.archive.org/web/20070627194553/http://www.mrctechnology.org/resources/PR/MRC_Humira_PRESS_RELEASE.pdf" class="external text external">"Multi-Million Dollar Deal To Benefit Medical Research"</a> <span class="cs1-format">(PDF)</span> (Press release). Medical Research Council. Archived from <a href="javascript:if(confirm('http://www.mrctechnology.org/resources/PR/MRC_Humira_PRESS_RELEASE.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mrctechnology.org/resources/PR/MRC_Humira_PRESS_RELEASE.pdf'" tppabs="http://www.mrctechnology.org/resources/PR/MRC_Humira_PRESS_RELEASE.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 27 June 2007<span class="reference-accessdate">. Retrieved <span class="nowrap">20 July</span> 2009</span>.</cite></span></li><li id="cite_note-64"> <span id="mw-reference-text-cite_note-64" class="mw-reference-text"><cite id="CITEREFPiersonSpicer2009" class="citation news cs1">Pierson R, Spicer J (30 June 2009). <a href="javascript:if(confirm('https://www.reuters.com/article/us-johnsonjohnson-abbott-humira-idUSTRE55T15Q20090630  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/us-johnsonjohnson-abbott-humira-idUSTRE55T15Q20090630'" tppabs="https://www.reuters.com/article/us-johnsonjohnson-abbott-humira-idUSTRE55T15Q20090630" class="external text external">"Jury returns $1.67 billion drug verdict against Abbott"</a>. <i>Reuters</i><span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-65"> <span id="mw-reference-text-cite_note-65" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://scholar.google.com/scholar_case?case=2674528643033496852  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://scholar.google.com/scholar_case?case=2674528643033496852'" tppabs="https://scholar.google.com/scholar_case?case=2674528643033496852" class="external text external">"Centocor Ortho Biotech v. Abbott Laboratories, 636 F. 3d 1341"</a>. Court of Appeals, Federal Circuit 2011. 23 February 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span> <span>–</span> via Google Scholar.</cite></span></li><li id="cite_note-66"> <span id="mw-reference-text-cite_note-66" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://caselaw.findlaw.com/us-federal-circuit/1556788.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://caselaw.findlaw.com/us-federal-circuit/1556788.html'" tppabs="https://caselaw.findlaw.com/us-federal-circuit/1556788.html" class="external text external">"Centocor Ortho Biotech Inc V. Abbott Laboratories"</a>. <i>FindLaw</i>. 23 February 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-67"> <span id="mw-reference-text-cite_note-67" class="mw-reference-text"><cite id="CITEREFDecker2011" class="citation news cs1">Decker S (23 February 2011). <a href="javascript:if(confirm('https://web.archive.org/web/20110506001424/http://www.businessweek.com/news/2011-02-23/abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20110506001424/http://www.businessweek.com/news/2011-02-23/abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory.html'" tppabs="https://web.archive.org/web/20110506001424/http://www.businessweek.com/news/2011-02-23/abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory.html" class="external text external">"Abbott Wins Reversal of J&amp;J's $1.67 Billion Patent Victory"</a>. <i>Bloomberg Businessweek</i>. Archived from <a href="javascript:if(confirm('http://www.businessweek.com/news/2011-02-23/abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.businessweek.com/news/2011-02-23/abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory.html'" tppabs="http://www.businessweek.com/news/2011-02-23/abbott-wins-reversal-of-j-j-s-1-67-billion-patent-victory.html" class="external text external">the original</a> on 6 May 2011.</cite></span></li><li id="cite_note-business-standard.com-68"> <span id="mw-reference-text-cite_note-business-standard.com-68" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('http://www.business-standard.com/article/companies/torrent-launches-world-s-second-biosimilar-of-generic-auto-immune-drug-116011100615_1.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.business-standard.com/article/companies/torrent-launches-world-s-second-biosimilar-of-generic-auto-immune-drug-116011100615_1.html'" tppabs="http://www.business-standard.com/article/companies/torrent-launches-world-s-second-biosimilar-of-generic-auto-immune-drug-116011100615_1.html" class="external text external">"Torrent launches world's second biosimilar of generic auto-immune drug"</a>. <i>Business Standard</i>. 11 January 2016.</cite></span></li><li id="cite_note-69"> <span id="mw-reference-text-cite_note-69" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024_toc.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024_toc.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761024_toc.cfm" class="external text external">"Drug Approval Package: Amjevita (adalimumab-atto)"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 9 November 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">11 February</span> 2020</span>.</cite></span></li><li id="cite_note-70"> <span id="mw-reference-text-cite_note-70" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/fda-approves-amjevita-biosimilar-humira  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/fda-approves-amjevita-biosimilar-humira'" tppabs="https://www.fda.gov/news-events/press-announcements/fda-approves-amjevita-biosimilar-humira" class="external text external">"FDA approves Amjevita, a biosimilar to Humira"</a>. <i>U.S. Food and Drug Administration (FDA)</i> (Press release). 23 September 2016. <a href="javascript:if(confirm('https://web.archive.org/web/20191119015605/https://www.fda.gov/news-events/press-announcements/fda-approves-amjevita-biosimilar-humira  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191119015605/https://www.fda.gov/news-events/press-announcements/fda-approves-amjevita-biosimilar-humira'" tppabs="https://web.archive.org/web/20191119015605/https://www.fda.gov/news-events/press-announcements/fda-approves-amjevita-biosimilar-humira" class="external text external">Archived</a> from the original on 19 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-71"> <span id="mw-reference-text-cite_note-71" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761024  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761024'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761024" class="external text external">"Amjevita: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-72"> <span id="mw-reference-text-cite_note-72" class="mw-reference-text"><cite id="CITEREFStanton2017" class="citation web cs1">Stanton D (3 October 2017). <a href="javascript:if(confirm('https://www.biopharma-reporter.com/Article/2017/10/03/Humira-biosimilar-settlement-a-win-win-for-Amgen-and-AbbVie-lawyer  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.biopharma-reporter.com/Article/2017/10/03/Humira-biosimilar-settlement-a-win-win-for-Amgen-and-AbbVie-lawyer'" tppabs="https://www.biopharma-reporter.com/Article/2017/10/03/Humira-biosimilar-settlement-a-win-win-for-Amgen-and-AbbVie-lawyer" class="external text external">"Humira biosimilar settlement a 'win-win' for Amgen and AbbVie, lawyer"</a>. <i>Biopharma-Reporter</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-73"> <span id="mw-reference-text-cite_note-73" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761058Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761058Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761058Orig1s000TOC.cfm" class="external text external">"Drug Approval Package: Cyltezo (adalimumab-adbm)"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 27 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">11 February</span> 2020</span>.</cite></span></li><li id="cite_note-74"> <span id="mw-reference-text-cite_note-74" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761058  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761058'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761058" class="external text external">"Cyltezo: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-75"> <span id="mw-reference-text-cite_note-75" class="mw-reference-text"><cite class="citation pressrelease cs1"><a href="javascript:if(confirm('https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-pharmaceuticals-inc-receives-fda-approval-cyltezo-adalimumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-pharmaceuticals-inc-receives-fda-approval-cyltezo-adalimumab'" tppabs="https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-pharmaceuticals-inc-receives-fda-approval-cyltezo-adalimumab" class="external text external">"Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo (adalimumab-adbm), a biosimilar to Humira, for the treatment of multiple chronic inflammatory diseases"</a> (Press release). Boehringer Ingelheim Pharmaceuticals. 29 August 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">19 March</span> 2019</span>.</cite></span></li><li id="cite_note-76"> <span id="mw-reference-text-cite_note-76" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/amgevita" class="external text external">"Amgevita EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-77"> <span id="mw-reference-text-cite_note-77" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/solymbic" class="external text external">"Solymbic EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-78"> <span id="mw-reference-text-cite_note-78" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/imraldi" class="external text external">"Imraldi EPAR"</a>. <i>European Medicines Agency (EMA)</i>. 17 September 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-79"> <span id="mw-reference-text-cite_note-79" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/cyltezo" class="external text external">"Cyltezo EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-80"> <span id="mw-reference-text-cite_note-80" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/halimatoz  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/halimatoz'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/halimatoz" class="external text external">"Halimatoz EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-81"> <span id="mw-reference-text-cite_note-81" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/hefiya  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/hefiya'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/hefiya" class="external text external">"Hefiya EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-82"> <span id="mw-reference-text-cite_note-82" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/hyrimoz" class="external text external">"Hyrimoz EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-83"> <span id="mw-reference-text-cite_note-83" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/hulio  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/hulio'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/hulio" class="external text external">"Hulio EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-BPR-oct-2018-84"> <span id="mw-reference-text-cite_note-BPR-oct-2018-84" class="mw-reference-text"><cite id="CITEREFHargreaves2018" class="citation web cs1">Hargreaves B (16 October 2018). <a href="javascript:if(confirm('https://www.biopharma-reporter.com/Article/2018/10/16/First-wave-of-Humira-biosimilars-enters-EU-market  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.biopharma-reporter.com/Article/2018/10/16/First-wave-of-Humira-biosimilars-enters-EU-market'" tppabs="https://www.biopharma-reporter.com/Article/2018/10/16/First-wave-of-Humira-biosimilars-enters-EU-market" class="external text external">"First wave of Humira biosimilars enters EU market"</a>. <i>BioPharma-Reporter</i><span class="reference-accessdate">. Retrieved <span class="nowrap">26 November</span> 2018</span>.</cite></span></li><li id="cite_note-85"> <span id="mw-reference-text-cite_note-85" class="mw-reference-text"><cite id="CITEREFHeal2018" class="citation news cs1">Heal A (26 November 2018). <a href="javascript:if(confirm('https://www.theguardian.com/society/2018/nov/26/nhs-replaces-highest-spend-drug-with-300m-cheaper-alternative  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.theguardian.com/society/2018/nov/26/nhs-replaces-highest-spend-drug-with-300m-cheaper-alternative'" tppabs="https://www.theguardian.com/society/2018/nov/26/nhs-replaces-highest-spend-drug-with-300m-cheaper-alternative" class="external text external">"NHS replaces highest-spend drug with £300m cheaper alternative"</a>. <i>The Guardian</i><span class="reference-accessdate">. Retrieved <span class="nowrap">26 November</span> 2018</span>.</cite></span></li><li id="cite_note-86"> <span id="mw-reference-text-cite_note-86" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.pharmaceutical-journal.com/20205612.article  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.pharmaceutical-journal.com/20205612.article'" tppabs="https://www.pharmaceutical-journal.com/20205612.article" class="external text external">"Most expensive NHS drug comes off patent"</a>. Pharmaceutical Journal. 18 October 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">29 November</span> 2018</span>.</cite></span></li><li id="cite_note-87"> <span id="mw-reference-text-cite_note-87" class="mw-reference-text"><cite id="CITEREFCalandraHuffButcher2019" class="citation web cs1">Calandra R, Huff C, Butcher L (25 January 2019). <a href="javascript:if(confirm('https://www.managedcaremag.com/archives/2019/1/bringing-humira-its-price-down-peg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.managedcaremag.com/archives/2019/1/bringing-humira-its-price-down-peg'" tppabs="https://www.managedcaremag.com/archives/2019/1/bringing-humira-its-price-down-peg" class="external text external">"Bringing Humira (Its Price) Down a Peg"</a>. <i>Managed Care magazine</i><span class="reference-accessdate">. Retrieved <span class="nowrap">9 September</span> 2019</span>.</cite></span></li><li id="cite_note-88"> <span id="mw-reference-text-cite_note-88" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071" class="external text external">"Hyrimoz: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 30 October 2018. <a href="javascript:if(confirm('https://web.archive.org/web/20191207062533/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191207062533/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071'" tppabs="https://web.archive.org/web/20191207062533/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761071" class="external text external">Archived</a> from the original on 7 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-89"> <span id="mw-reference-text-cite_note-89" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761071Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761071Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761071Orig1s000TOC.cfm" class="external text external">"Drug Approval Package: Hyrimoz"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 21 March 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 February</span> 2020</span>.</cite></span></li><li id="cite_note-90"> <span id="mw-reference-text-cite_note-90" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/idacio  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/idacio'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/idacio" class="external text external">"Idacio EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-91"> <span id="mw-reference-text-cite_note-91" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/kromeya  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/kromeya'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/kromeya" class="external text external">"Kromeya EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-92"> <span id="mw-reference-text-cite_note-92" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761059  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761059'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761059" class="external text external">"Hadlima: FDA-Approved Drugs"</a>. U.S. Food and Drug Administration (FDA)<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-93"> <span id="mw-reference-text-cite_note-93" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761059Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761059Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761059Orig1s000TOC.cfm" class="external text external">"Drug Approval Package: Hadlima"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 5 September 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">11 February</span> 2020</span>.</cite></span></li><li id="cite_note-94"> <span id="mw-reference-text-cite_note-94" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.beckershospitalreview.com/pharmacy/fda-approves-humira-biosimilar-but-it-won-t-hit-the-market-for-4-years.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.beckershospitalreview.com/pharmacy/fda-approves-humira-biosimilar-but-it-won-t-hit-the-market-for-4-years.html'" tppabs="https://www.beckershospitalreview.com/pharmacy/fda-approves-humira-biosimilar-but-it-won-t-hit-the-market-for-4-years.html" class="external text external">"FDA approves Humira biosimilar, but it won't hit the market for 4 years"</a>. Becker's Hospital Review. 24 July 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">8 November</span> 2019</span>.</cite></span></li><li id="cite_note-95"> <span id="mw-reference-text-cite_note-95" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761118  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761118'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761118" class="external text external">"Abrilada: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 15 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191207063708/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761118  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191207063708/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761118'" tppabs="https://web.archive.org/web/20191207063708/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761118" class="external text external">Archived</a> from the original on 7 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">6 December</span> 2019</span>.</cite></span></li><li id="cite_note-96"> <span id="mw-reference-text-cite_note-96" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000TOC.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000TOC.cfm'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761118Orig1s000TOC.cfm" class="external text external">"Drug Approval Package: Abrilada"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 28 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">11 February</span> 2020</span>.</cite></span></li><li id="cite_note-97"> <span id="mw-reference-text-cite_note-97" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/news-events/press-announcements/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/news-events/press-announcements/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug'" tppabs="https://www.fda.gov/news-events/press-announcements/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug" class="external text external">"Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA's Center for Drug Evaluation and Research, on FDA's continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product"</a>. <i>U.S. Food and Drug Administration (FDA)</i>. 15 November 2019. <a href="javascript:if(confirm('https://web.archive.org/web/20191119020728/https://www.fda.gov/news-events/press-announcements/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20191119020728/https://www.fda.gov/news-events/press-announcements/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug'" tppabs="https://web.archive.org/web/20191119020728/https://www.fda.gov/news-events/press-announcements/statement-sarah-yim-md-acting-director-office-therapeutic-biologics-and-biosimilars-fdas-center-drug" class="external text external">Archived</a> from the original on 19 November 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">18 November</span> 2019</span>.</cite> <figure-inline><span><img src="../I/m/PD-icon.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/PD-icon.svg.png" data-file-width="196" data-file-height="196" data-file-type="drawing" height="15" width="15"></span></figure-inline><span> </span><i>This article incorporates text from this source, which is in the public domain.</i></span></li><li id="cite_note-98"> <span id="mw-reference-text-cite_note-98" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity'" tppabs="https://www.ema.europa.eu/en/medicines/human/EPAR/amsparity" class="external text external">"Amsparity EPAR"</a>. <i>European Medicines Agency (EMA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">18 February</span> 2020</span>.</cite></span></li><li id="cite_note-99"> <span id="mw-reference-text-cite_note-99" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761154  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761154'" tppabs="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761154" class="external text external">"Hulio: FDA-Approved Drugs"</a>. <i>U.S. Food and Drug Administration (FDA)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">7 July</span> 2020</span>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/adalimumab  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/adalimumab'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/adalimumab" class="external text external">"Adalimumab"</a>. <i>Drug Information Portal</i>. US National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_the_immune_system" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2" style="text-align:center;"><div id="Monoclonal_antibodies_for_the_immune_system" style="font-size:114%;margin:0 4em">Monoclonal antibodies for the immune system</div></th></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Immune system</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppression</i>: Abrilumab</li>
<li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Anifrolumab<sup>†</sup></li>
<li>Atorolimumab</li>
<li>Avelumab</li>
<li>Belimumab</li>
<li>Bleselumab</li>
<li>Brodalumab</li>
<li>Camidanlumab tesirine</li>
<li>Carlumab</li>
<li>Cemiplimab</li>
<li>Dupilumab</li>
<li>Eldelumab</li>
<li>Emapalumab<sup>†</sup></li>
<li>Fresolimumab</li>
<li>Golimumab</li>
<li>Ianalumab<sup>†</sup></li>
<li>Lanadelumab</li>
<li>Lenzilumab</li>
<li>Lerdelimumab</li>
<li>Lirilumab</li>
<li>Mavrilimumab</li>
<li>Metelimumab</li>
<li>Morolimumab</li>
<li>Namilumab</li>
<li>Oleclumab</li>
<li>Oxelumab§</li>
<li>Pamrevlumab</li>
<li>Placulumab</li>
<li>Relatlimab<sup>†</sup></li>
<li>Sarilumab</li>
<li>Sifalimumab</li>
<li>Tabalumab</li>
<li>Tezepelumab<sup>†</sup></li>
<li>Ulocuplumab</li>
<li>Varlilumab</li></ul>

<ul><li><i>Immune activation</i>: Ipilimumab</li>
<li>Atezolizumab</li>
<li>Durvalumab</li>
<li>Nivolumab</li>
<li>Pembrolizumab</li>
<li>Tremelimumab<sup>†</sup></li>
<li>Urelumab</li></ul>

<ul><li><i>Other</i>: Bertilimumab</li>
<li>Zanolimumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Afelimomab</li>
<li>Elsilimomab</li>
<li>Faralimomab</li>
<li>Gavilimomab</li>
<li>Inolimomab</li>
<li>Maslimomab</li>
<li>Nerelimomab</li>
<li>Odulimomab</li>
<li>Telimomab aritox</li>
<li>Vepalimomab</li>
<li>Zolimomab aritox</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Andecaliximab<sup>†</sup></li>
<li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li>Clenoliximab</li>
<li>Galiximab</li>
<li>Gomiliximab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Keliximab</li>
<li>Lumiliximab</li>
<li>Priliximab</li>
<li>Teneliximab</li>
<li>Vapaliximab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Immunosuppressive:</i> Aselizumab</li>
<li>Apolizumab<sup>§</sup></li>
<li>Benralizumab</li>
<li>Camrelizumab<sup>†</sup></li>
<li>Cedelizumab</li>
<li>Certolizumab pegol</li>
<li>Crizanlizumab<sup>†</sup></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Dostarlimab<sup>†</sup></li>
<li>Eculizumab</li>
<li>Efalizumab<sup>‡</sup></li>
<li>Epratuzumab</li>
<li>Erlizumab</li>
<li>Etrolizumab<sup>†</sup></li>
<li>Fontolizumab</li>
<li>Inebilizumab</li>
<li>Itolizumab</li>
<li>Lampalizumab<sup>†</sup></li>
<li>Letolizumab</li>
<li>Ligelizumab<sup>†</sup></li>
<li>Lulizumab pegol</li>
<li>Mepolizumab</li>
<li>Mogamulizumab</li>
<li>Natalizumab</li>
<li>Ocrelizumab</li>
<li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li>
<li>Ozoralizumab</li>
<li>Pascolizumab</li>
<li>Pateclizumab</li>
<li>Pembrolizumab</li>
<li>Pexelizumab</li>
<li>Pidilizumab</li>
<li>Plozalizumab</li>
<li>PRO 140<sup>†</sup></li>
<li>Quilizumab</li>
<li>Ravulizumab</li>
<li>Reslizumab</li>
<li>Rontalizumab</li>
<li>Rovelizumab</li>
<li>Ruplizumab</li>
<li>Samalizumab</li>
<li>Satralizumab</li>
<li>Siplizumab</li>
<li>Spartalizumab<sup>†</sup></li>
<li>Talizumab</li>
<li>Teplizumab</li>
<li>Tislelizumab</li>
<li>Tocilizumab</li>
<li>Toralizumab</li>
<li>Tregalizumab</li>
<li>Vatelizumab</li>
<li>Vedolizumab</li>
<li>Visilizumab</li>
<li>Vobarilizumab</li>
<li>TGN1412<sup>§</sup><br><i>Non-immunosuppressive:</i> Ibalizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Chimeric + humanized<br></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Otelixizumab</li>
<li>Sutimlimab<sup>†</sup></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Interleukin</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Human</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Bermekimab</li>
<li>Brazikumab</li>
<li>Briakinumab</li>
<li>Canakinumab</li>
<li>Fezakinumab</li>
<li>Fletikumab</li>
<li>Guselkumab</li>
<li>Secukinumab</li>
<li>Sirukumab</li>
<li>Tralokinumab<sup>†</sup></li>
<li>Ustekinumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Humanized</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anrukinzumab</li>
<li>Bimekizumab<sup>†</sup></li>
<li>Clazakizumab</li>
<li>Gevokizumab</li>
<li>Ixekizumab</li>
<li>Mirikizumab<sup>†</sup></li>
<li>Lebrikizumab</li>
<li>Olokizumab<sup>†</sup></li>
<li>Perakizumab</li>
<li>Risankizumab</li>
<li>Tildrakizumab</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Veterinary</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Lokivetmab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="text-align:center;;width:1%">Inflammatory lesions</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th id="Mouse" scope="row" class="navbox-group" style="width:1%;text-align:center;">Mouse</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Besilesomab</li>
<li>Fanolesomab<sup>‡</sup></li>
<li>Lemalesomab</li>
<li>Sulesomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="text-align:center;;background: transparent; padding: 0px;"><div><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div></div></td></tr></tbody></table></div>







<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-08-13" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Adalimumab&oldid=972627845  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Adalimumab&oldid=972627845'" tppabs="https://en.wikipedia.org/wiki/?title=Adalimumab&oldid=972627845">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>